Remgro

Mediclinic Results: Mediclinic’s group revenue rose 5% to $4.6bn. Adjusted EBITDA fell 2% to $673m (FY23: $685m), leading to a margin drop to 14.7% from 15.8%. Adjusted earnings remained flat at $230m (FY23: $229m). Net debt rose by 8% to $1.5m (FY23: $1.4m). Results impacted by a weak performance in Switzerland but partially offset by strong performance in the Middle East.
Click here to read the SENS